BioStem Technologies has signed a Letter of Intent (“LOI”) with CCM Pharma Solutions (CCM). CCM has identified several drugs in the cardiovascular, metabolic disease and CNS disease space, some of which represent over a billion dollars in annual sales. BSEM and CCM will co-develop NDA and ANDA drugs through the 505(b)(2) accelerated FDA approval process.   BioStem’s current development effort is increasingly directed towards improved solid-to-liquid drugs which follow an NDA 505(b)(2) re...